Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02870205 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)
A Phase 3 study, sponsored by Glenmark Specialty S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,176
- Enrollment target
NCT02870205 is a Phase 3 study that has completed, run by Glenmark Specialty S.A.. The registered enrollment target is 1,176 participants.
The verdict
NCT02870205, a Phase 3 study, has completed, sponsored by Glenmark Specialty S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,176 participants
- Enrollment target
Study Summary
Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis (subjects 12 years of age and older)
Interventions
- DRUG GSP 301 NS
- DRUG GOM-NS
- DRUG GMM-2 NS
- DRUG GSP 301 placebo NS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,176 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02870205
The ClinicalTrials.gov registry entry for NCT02870205 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glenmark Specialty S.A., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which GSP 301 NS is the first listed.
NCT02870205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02870205 about?
NCT02870205 is a clinical study titled "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)". Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis (subjects 12 years of age and older)
What is the current status of trial NCT02870205?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,176 participants. The study started on 2016-08. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02870205?
The interventions under investigation include: GSP 301 NS (DRUG), GOM-NS (DRUG), GMM-2 NS (DRUG), GSP 301 placebo NS (DRUG).
Who is sponsoring clinical trial NCT02870205?
This trial is sponsored by Glenmark Specialty S.A., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.